ZHIFEI-BIOL
30012212.902.14% ( +0.27 )
ZHIFEI-BIOL (300122)
Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vacc...
- Open
- 12.54
- High
- 13.08
- Low
- 12.53
- Prev. Close
- 12.63
- Volume
- 285.38K
- Turnover
- 367.87M
- Avg Price
- 12.89
- Bid/Ask Ratio
- --
- Amplitude
- 4.35%
- 52wk High
- 26.00
- Volume Ratio
- 0.75
- Turnover Ratio
- 1.19%
ZHIFEI-BIOL Analyst Rating
View MoreForecast & Rating
Jul 17, 2026Price forecast
¥21.1764.08%
Forecast & RatingBuy
3analysts
- Strong buy33.33%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell33.33%
News
- CoinLive · Apr 2 at 06:55 AM
Zhifei Biological and Merck Sign Revised Agreement to Enhance Strategic Cooperation
- Wallstreetcn · Mar 16 at 03:33 AM
ZHIFEI-BIOL: The improved Ankara strain vaccinia virus (MVA) monkeypox live attenuated vaccine has received clinical trial approval notification
- Wallstreetcn · Feb 9 at 02:09 AM
ZHIFEI-BIOL: The recombinant varicella-zoster virus ZFA01 adjuvanted vaccine (CHO cells) has received the clinical trial approval notice
- Wallstreetcn · Jan 12 at 04:44 PM
ZHIFEI-BIOL expects a net loss attributable to shareholders of the listed company of RMB 10.6979361 billion to RMB 13.7256538 billion in 2025, compared to a profit of RMB 2.0184785 billion in the previous year
- Wallstreetcn · Jan 12 at 04:35 AM
ZHIFEI-BIOL: CA111 injection has entered Phase I clinical trials
- Zhitong · Oct 29, 2025 at 05:01 PM
ZHIFEI-BIOL released its performance for the first three quarters, with a net loss attributable to the parent company of 1.206 billion yuan
